Lisata Therapeutics Inc (LSTA)

[Viperciara]

NeoStem Inc 387.8% Potential Upside Indicated by The Benchmark Company
NeoStem Inc using SYMBOL code NASDAQ:NBS has had its stock rating noted as ‘Reiterated’ with the recommendation being set at ‘BUY’ this morning by analysts at The Benchmark Company. NeoStem Inc are listed in the Health Care sector within NASDAQ. The Benchmark Company have set a target price of 12 USD on its stock. This is indicating the analyst believes there is a potential upside of 387.8% from the opening price of 2.46 USD. NeoStem Inc NASDAQ:NBS has a 50 day moving average of 3.33 USD and a 200 Day Moving Average share price is recorded at 4.45 USD. The 52 week high for the share price is currently at 7.23 USD while the 52 week low for the share price is 2.34 USD.



NeoStem Inc NASDAQ:NBS is a provider of cellular therapy products. The Company is engaged in the development of cell therapy products; it also provides development and manufacturing services. NeoStem’s research and clinical development activities are aimed at three therapeutic platforms: ischemic repair (CD34 Cell Program), immune modulation (T Regulatory Cell Program) and tissue regeneration (VSELTM Technology). The Company develops therapies to address ischemia through its CD34 Cell Program. The Company focuses on the development of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs, restoring their normal function. The Company’s AMR-001 is the product candidate in its CD34 Cell Program and is being developed to treat damaged heart muscle following an acute myocardial infarction (heart attack) (AMI
http://www.directorstalkinterviews.com/neostem-inc-387-8-potential-upside-indicated-by-the-benchmark-company/412662602